Stock Alert: Satsuma Pharmaceuticals Plunges 73% As Late Stage Trial Of Migraine Treatment Fails

Shares of Satsuma Pharmaceuticals, Inc. (STSA) tanked 73% on Thursday morning after a late stage trial of its migraine treatment failed to meet primary endpoints.

STSA is currently trading at $6.17, down $17.17 or 73.56%, on the Nasdaq.

Satsuma, a clinical-stage biopharmaceutical company, while announcing the outcome of Phase 3 efficacy trial of STS101 (dihydroergotamine nasal) powder as an acute treatment for migraine, said the trial did not meet primary endpoints.

The company said that the drug did not show any statistical significance difference on the co-primary endpoints of freedom from pain and most bothersome symptoms like photophobia, phonophobia and nausea at two hours post-administration.

However, both dosage strengths of STS101 did demonstrate significant effects on both freedom from pain and most bothersome symptom by three hours post-dose and later time points.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Financial services firm Morgan Stanley (MS) reported Wednesday a profit for the fourth quarter that increased 10 percent from last year, reflecting 7 percent revenue growth amidst strength in Wealth Management and Investment Management business segments. Bank of America Corp. (BAC) reported Thursday that net income applicable to common shareholders for the fourth quarter grew 30 percent to $6.77 billion from last year's $5.21 billion, with earnings per share increasing to $0.82 from $0.59 in the prior year, reflecting strong operating leverage as revenues... Shares of ASML Holding N.V. were gaining more than 1 percent in Amsterdam trading after the Dutch semiconductor equipment maker reported Wednesday higher profit and net sales in its fourth quarter. The company also projects higher sales in fiscal 2022, and a 100 percent increase in total dividend.
Follow RTT